Market Estimates on Congestive Heart Failure - Pipeline Review, H2 2016

Congestive Heart Failure (Heart Failure) - Pipeline Review, H2 2016 ​is a new market research publication announced by Reportstack. This report provides an overview of the Congestive Heart Failure (Heart Failure) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Congestive Heart Failure (Heart Failure), complete with analysis by stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Congestive Heart Failure (Heart Failure) and features dormant and discontinued projects.

Complete report available @ Congestive Heart Failure (Heart Failure) - Pipeline Review, H2 2016

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape of Congestive Heart Failure (Heart Failure)
- The report reviews pipeline therapeutics for Congestive Heart Failure (Heart Failure) by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report reviews key players involved Congestive Heart Failure (Heart Failure) therapeutics and enlists all their major and minor projects
- The report assesses Congestive Heart Failure (Heart Failure) therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Congestive Heart Failure (Heart Failure)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to 

- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Congestive Heart Failure (Heart Failure) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies Mentioned

Amgen Inc. AnGes MG, Inc. Araim Pharmaceuticals, Inc. ARCA biopharma, Inc. Ascelegen Therapeutics, Inc. Asterias Biotherapeutics, Inc. Athersys, Inc. Bayer AG BEAT BioTherapeutics Corp. BioCardia, Inc. Bristol-Myers Squibb Company Capricor Therapeutics, Inc. Cell Therapy Limited Celyad SA Eli Lilly and Company FibroGen, Inc. GlaxoSmithKline Plc Glucox Biotech AB Heart Metabolics Limited Hemostemix Ltd Innopharmax Inc. Jiangsu Hengrui Medicine Co., Ltd. Juventas Therapeutics, Inc. La Jolla Pharmaceutical Company Laboratoires Pierre Fabre SA Lead Discovery Center GmbH Lee's Pharmaceutical Holdings Limited Les Laboratoires Servier SAS Lonestar Heart, Inc. Mast Therapeutics, Inc. Merck & Co., Inc. Mesoblast Limited miRagen Therapeutics, Inc. MorphoSys AG NanoCor Therapeutics, Inc. Neurocrine Biosciences, Inc. Novartis AG Nuo Therapeutics, Inc. Ono Pharmaceutical Co., Ltd. Palatin Technologies, Inc. Pfizer Inc. PharmaIN Corporation PhaseBio Pharmaceuticals, Inc. Pluristem Therapeutics Inc. Quantum Genomics SA Recardio GmbH RedHill Biopharma Ltd. Renova Therapeutics Inc scPharmaceuticals Inc Stealth BioTherapeutics Inc. Stemedica Cell Technologies, Inc. Target Heart Biotec Srl Theravance Biopharma, Inc. TiGenix NV Torrent Pharmaceuticals Limited Trevena, Inc. U.S. Stem Cell, Inc. Vichem Chemie Research Ltd. Vicore Pharma AB Zensun (Shanghai) Sci & Tech Co., Ltd.

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

Reportstack Market Research

###